Literature DB >> 29240584

Dermatofibrosarcoma Protuberans of Distal Extremities and Acral Sites: A Clinicopathologic Analysis of 27 Cases.

Kabeer K Shah1, Jonathan B McHugh2, Andrew L Folpe1, Rajiv M Patel2,3.   

Abstract

Dermatofibrosarcoma protuberans (DFSP) of the distal extremities and acral sites are extremely rare and incompletely characterized. Twenty-seven DFSP occurring in these sites were retrieved from our collective archives and reevaluated. Tumors occurred in 16 males and 11 females. Median age at presentation was 42.5 years (range, 7 to 78 y). Lesions involved the foot (18 with 6 in the toes and 2 on the plantar foot), distal ankle (4), hand (4 with 2 in the thumbs), and wrist (1). All cases showed predominantly classic DFSP morphology and were diffusely CD34 positive. Myxoid change, melanin pigmented, and giant cell fibroblastoma foci were each present in 1 case, respectively. Fibrosarcomatous change was present in 3 cases. Fluorescent in situ hybridization demonstrated PDGFB gene rearrangement in 9 of 10 tested cases. Clinical follow-up was available in 21 cases (median, 36.1 mo; range, 1 to 152 mo) and revealed 4 local recurrences. Four patients underwent digital amputation for unresectable recurrent disease. An additional patient underwent multiple resections with positive margins and elected to receive imatinib mesylate therapy. After a 2-year course, the patient has no evidence of residual disease (40 mo). No metastases were documented in any of the cases studied. The natural history of DFSP of distal extremities and acral sites is similar to that of its counterparts elsewhere. A high index of suspicion, careful morphologic examination for key histologic features of DFSP, and in selected cases, molecular studies to identify the pathognomonic COL1A1-PDGFB gene fusion should facilitate the distinction of these rare, locally aggressive neoplasms from morphologic mimics that may arise in distal extremities and acral sites.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29240584     DOI: 10.1097/PAS.0000000000000998

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  8 in total

1.  Dermatofibrosarcoma protuberans of the hallux: A case report with review of the literature.

Authors:  Rafik Elafram; Majdi Ben Romdhane; Nayssem Khessairi; Majdi Sghaier; Hedi Annabi
Journal:  Int J Surg Case Rep       Date:  2022-06-22

2.  Dermatofibrosarcoma protuberance in a black African cohort-a clinicopathologic study.

Authors:  Gabriel Olabiyi Ogun; Uchenna Simon Ezenkwa; Omobolaji Oladayo Ayandipo
Journal:  Ecancermedicalscience       Date:  2020-08-07

Review 3.  The efficacy of Mohs micrographic surgery over the traditional wide local excision surgery in the cure of dermatofibrosarcoma protuberans.

Authors:  Malumani Malan; Wu Xuejingzi; Song Ji Quan
Journal:  Pan Afr Med J       Date:  2019-08-13

Review 4.  A Rare Malignant Disease, Dermatofibrosarcoma Protuberans of the Breast: A Retrospective Analysis and Review of Literature.

Authors:  Yihua Wang; Yu Wang; Rui Chen; Zhenrong Tang; Shengchun Liu
Journal:  Biomed Res Int       Date:  2020-11-09       Impact factor: 3.411

5.  Dermatofibrosarcoma Protuberans in the Palm of a 3-Year-Old Child.

Authors:  Omer Faruk Kumbuloglu; Fatih Barishan; Fevziye Kabukcuoglu; Haci Mustafa Ozdemir
Journal:  Dermatol Pract Concept       Date:  2022-01-01

Review 6.  Preoperative 3D Reconstruction Model in Slow Mohs Surgery for Dermatofibrosarcoma Protuberans.

Authors:  Jia Huang; Xiaobo Zhou; Songtao Ai; Jun Chen; Jun Yang; Di Sun
Journal:  Comput Intell Neurosci       Date:  2022-04-07

7.  Myoid differentiation in dermatofibrosarcoma protuberans and its fibrosarcomatous variant: 10 years' experience in a tertiary hospital.

Authors:  Chun-Hai Lo; Po-Man Tsang; Shui-Ying Cheng
Journal:  Autops Case Rep       Date:  2022-04-01

8.  Dermatofibrosarcoma protuberans in a young patient with epidermolysis bullosa: a case report.

Authors:  B Bonaventura; D Kraus; G B Stark; H Fuellgraf; J Kiefer
Journal:  BMC Surg       Date:  2021-02-23       Impact factor: 2.102

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.